-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LpcTvXfG+5XzYBaXTp5TNIVy1IIn5btO+G6/dFkLdIzNdfuL2oSbKRUikLeFE0Ob
 +fy0nILutG1ODAed4T/Qkg==

<SEC-DOCUMENT>0001193125-10-228190.txt : 20101012
<SEC-HEADER>0001193125-10-228190.hdr.sgml : 20101011
<ACCEPTANCE-DATETIME>20101012172015
ACCESSION NUMBER:		0001193125-10-228190
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101012
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101012
DATE AS OF CHANGE:		20101012

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		101119942

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): October&nbsp;12, 2010 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>BRISTOL-MYERS SQUIBB COMPANY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-1136</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22-079-0350</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number) </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>345 Park Avenue </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY, 10154 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Office) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (212)&nbsp;546-4000 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item 8.01. Other Events. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;12, 2010, Bristol-Myers Squibb Company (the &#147;Company&#148;) announced the completion of the acquisition of all outstanding shares of
common stock, without par value (the &#147;Shares&#148;), of ZymoGenetics, Inc., a Washington corporation (&#147;ZymoGenetics&#148;), that were not already owned by the Company and its subsidiaries.&nbsp;The acquisition of the Shares was structured
as a two-step transaction, with a cash tender offer by Zeus Acquisition Corporation, a Washington corporation and a wholly owned subsidiary of the Company (the &#147;Purchaser&#148;), for the Shares at a price of $9.75 per Share, net to the seller
in cash, without interest and less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated September&nbsp;10, 2010, and in the related Letter of Transmittal, each as amended and
supplemented, filed by the Company and the Purchaser with the Securities and Exchange Commission on September&nbsp;10, 2010, followed by the merger of ZymoGenetics with and into Purchaser.&nbsp;The press release is attached as Exhibit 99.1 to this
Current Report and is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exhibits. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated October&nbsp;12, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">BRISTOL-MYERS SQUIBB COMPANY</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: October&nbsp;12, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sandra Leung</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sandra Leung</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel and Secretary</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated October 12, 2010.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE DATED OCTOBER 12, 2010
<TEXT>
<HTML><HEAD>
<TITLE>Press release dated October 12, 2010</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g107814ex99_1page1.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(NEW YORK, October&nbsp;12, 2010)<B>&nbsp;</B>&#151; Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its
previously announced acquisition of ZymoGenetics, Inc. (NASDAQ: ZGEN).&nbsp;As a result of the transaction, ZymoGenetics has become a wholly-owned subsidiary of Bristol-Myers Squibb. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bristol-Myers Squibb initiated on September&nbsp;10, 2010, a cash tender offer to purchase all outstanding shares of common stock of
ZymoGenetics for $9.75 per share.&nbsp;The tender offer period expired at midnight (New York City time) on October&nbsp;7, 2010, and was not extended. Based on information provided by the Depositary to Parent, as of the expiration of the Offer,
approximately 82,605,529 Shares were validly tendered and not validly withdrawn prior to the expiration of the Offer, representing approximately 94.9% of the ZymoGenetics shares outstanding. As of the close of business on October&nbsp;11, 2010,
approximately 981,756 Shares remained subject to guaranteed delivery procedures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Today, Bristol-Myers Squibb acquired all of
the remaining outstanding shares of ZymoGenetics common stock by means of a &#147;short form merger&#148; in which all such shares were converted into the right to receive $9.75 per share, in cash and without interest, less any required withholding
taxes. Bristol-Myers Squibb intends to delist and de-register ZymoGenetics common stock as promptly as practicable following the effective time of the merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of ZymoGenetics. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>About Bristol-Myers Squibb </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases. For more information, please visit <U>www.bms.com</U> or follow us on Twitter at <U>http://twitter.com/bmsnews</U>. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Media:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jennifer Fron Mauer, (609) 252-6579, <U>jennifer.mauer@bms.com</U></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investors:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teri Loxam, (609) 252-3368, <U>teri.loxam@bms.com</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suketu Desai, (609) 252-5796, <U>suketu.desai@bms.com</U></FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g107814ex99_1page1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107814ex99_1page1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`%P#P`P$1``(1`0,1`?_$`)$```("`P$!`0``````
M``````<(!`8``P4!`@H!``(#`0$!``````````````0%``,&!P(!$```!P`!
M!`(!!`("`P`````!`@,$!08'"``1$A,4%18A(A<),2-!)3,D&!$``@$$`0,#
M`P0!!`(#`````0(#$1($!2$`$P8Q(A1!,A5"(S,'85%Q)!:10U)B)?_:``P#
M`0`"$0,1`#\`_=SH=ADX>'^MK8I?E]A3?,*ZHNDFX:QBJ+)5P\L<BW4.0JT7
M7T"^Y0@B`+JBDAW*98H@YTF#!E9/>SN-=#0O]WO)-$A!4$AI6]H;]*W/R$(Z
M4[C-DP\0]BOR'#`&@(0!2S2,#P0B@M3DL:*!STG-:DM#8NYLMFOMJL4Z:-A+
M$2'?V=]6X>8;SC2%(I+U1[66BH0\>DY=BY/&F0>))E66216*1H(CTK/Q=+)C
MB'%P\>!5GDBO11(\?;>2B3]T"]G10%D4H;@H96[E%RN+E[8DI([OGF-).V[F
M-2&"*2K)PHJ>X4M8$DHI%A/4VOS.K,[PXGZI=K-<:LTM*4`_@94$Y.&M2<=6
MK;8)*%IOSUU7\,[(W;@N1\=TZ6=BV8)B0B;E<0KSM;H'P?C;''CQ-E\8O</8
M8;IHHEDF"BUQ4JK1T18ZS,"64*9AMOFR5R<3),V-W26#T"R`+(>Q$""5`H&6
M4LSL+`U`&7IZHR28S,<QEHUP1U'R+5!ZS<$\@*LW<)E52/XF`IR")#?J4P`8
MH_H(`("'7)9H9,>5H)A;*C$$?Y'6[@F3(A2>.MCJ&%10T(KR#R#_`*@\@\'H
M!W?D?!4_8J_@\?0M(NVC66G2=]CF=9BH!I!%K$.[3CY%\YM%NLM7@RJMGRZ2
M)D$UE5P463`2@!RB.AP_%\G*TA\ADR,6'5KD"%BSL75R*BL<:.X!%2#2AH:>
MG2/*\CQL?<KX_'%/)M7@,R*`%1D4T8B1V5*J:!A6HJ..>K9B^U5'<ZU,V&J-
MI^*7JUQL>>W&LVN,+$6:HW:IN$V\[7)MDDY?,_E-?D)*D5;.'+5P@LFJDJ<A
MP'JGR3QK8^+YL>'L#$ZSX\<\4D371RPRBJ2(2%:AH11E5@001T5IMWA[S'DG
MPQ(K0S-#(DBV/'*E+D=?H14'@D$$%25()MQ;W7#WY7-"N'PVU&IIW91M]/+A
M&A7U9<T(18)\6001GHR!1+\0'`NO#_9Z_#]W2\ZS+&K&X(3X1G[(]Z7WVW_Q
MUOMI^NVVM!6IZ(&QQCLSJ1?\L0=W[&LL+6??2RZOZ*W4]U*<]=::L=?K@19K
M!-Q4($Y-1]<AAE7[5@$K8)8YTXN$COE*I?,E9%1,P(-T_)542CXE'L/5&-A9
MF9W/B122]F)I'M4M9&M+G:@-J+458\"HJ>K\C+Q<2SY4B1]V01I<P6YVK:BU
M]6-#11R:'KM=#=$="B@[)4]&N6M46";6!K/XO9XJIW%*<AU8I`\C-P+2RQCJ
M$465,>5B7D.^253<E(5-0#_M$W8>SO9^/[#4Z_"V>59\381-)"5-U51K&KQ0
M,K54K4D$$&G2K"V^+GYV5KH1(,C#9%DN4J*NMRVD_<"O-:4H12O59L7)#.:C
MO%)X\6@)Z"N^DU^7GZ#)OXQ(M/M8P()'EH.-GDGJOJL;5%3V`T<(H&6(4PI"
M<0[=%XWBFRS/')O)\)H9<+&<+,BL>]$&-%=T*@=LFGN5F`J+J=59'D&MQ-S!
MH<EBF?DJ6BJ/;):"6"FOW*%)(('TI6O6C4.3.:Y1J&18U.?D$SH^UR3UC3JW
M5XM*5<-VD<F99[/V159ZR0@:\BFDJ(.53#[1;JE3*<R9@":GQ/:;C2YV_@,,
M>MP%4R-(Q4L6(`6,!6+L"RW>@4,I)%1U\V/D.MUFPQM5D%SL,N[M(JDUL!)J
M?M7@&EQ%2*"IXZ83K,].^LZG4ZSJ=3KC6*P0U2K\[:K'((1->K,/)V"=E'/D
M#:-AH9DO(R;]P)"G/Z&;)L=0_8!'Q*/8!ZOQ<:?-R8\/&6[)ED5$7@59B%4<
MT')(')IU1DY,&'CR9>2P3&B1G=CZ*J@EB?\```)Z6?/^7E2T.8S5FRR_<J]7
M-@(Y6S?0[704(JC6-J2!?6:+=*/T)U]+5XEE@X\[B,)*LF*SLAB]B`(]@U6S
M\+S-7#DNV7@39.'_`#PQ2EI8B'$;`AD56M<A6[;/3_8&B'`\HQ<]<>08^7%C
MY9':>2,!6#(75JAF*AP**'"L2150#7IL>L=UI>LZG4Z7:0Y2Y"S<T)NTD;#-
M)Z)LDO@L(^B*C8E(YGI<",J$M#SSU['L4(9JU&$=@1TJ/QW(H&!`RH]N^I@\
M/W$T67))V(FQ,),MD>50[0N%*F-%+,Y(92106`@O:.DDOD&LAGA@D9PTV2V.
MIL:WO+R4)(H"0#:?1J&A-#U<=3V:F8Z:@!<BSQ2:3H=;S"N+PT!(S+9.U6MP
M9K#)3+EDD="%8.%B"7Y#@Q"=P[!W-V#H+3>/Y^]3*?`[?_#QGGD#,`W;058J
MO+-3ZT%!47$`UZ+S]ECZXP_(#TFF6)2%)`9S1;CZ*">*D@5X')`)8Z1],.EJ
MN'*6AUS0YK**W6M'UK0JI'1<M>:YE%3_`"4U"CYU$[F!/<)9](0D!%/IULD=
M5HP!VI(+(D%4J'K[''8:_P`+V&9JX]UF9&%@:R9RD3Y,I0S%3:_;1%DD*I^M
MR@0>EQ)`.?R/),*+,EU^+'/E9D`4RK`E_;OK:'8E4#4!-EQ>VAMH14J9=I,)
MK5*C+S7XZRP[&2<2K)6%N4`]JUJAY"%E7L-)1L]7I(I'T3(-GS$X"DH`&\!*
M;_!@Z0;;63:?.?`G>*1U"D/&U\;JRAE9&XJI!!!H.F6MV$&TQ1EP!U6YE*NM
MKJRL5967Z$$=$'I=T=UG4ZG6=3J=9U.IUG4ZG6=3J=);JS2U_P`S/UY)-ZO2
MUJ7#J-1DG2*]-:QD=(.5K,>5B8B$5GUFA)%1H9\+E9U'`!FIG"14RD$.M^-3
M:9?$XS(RKG1Y4G$8(R&D90$-[R*@_;J(@H5^);#>37G^ZAVGYR::10=.<9.7
MJT0*EB%:-%+FD@#.WN6Q@&%`.@!;$V:LU!GEF=L?T(\$I)`QRY9O&?8MEGS1
M6.7I,9,QK2Q(5HZGREC`R-'QQV!'Y6Z3CV`"FMP\AUQ)(];-`NVDF$5V72JT
M4W_(=9&@,@]BEI+I`W9+NMIHAV,2020G*20Z\(S5QV*@W/$%[0I?;4DFT*A0
M.8U-2!9*"0Y:G%$L*+1Y)K_8,*LYGE7LS+2DV22E7BQ,^7H]?9Q,98`0.H82
M1J3.1^,(J*=D2"IT/M)\.3*OB>4PJX:80JBQQQD+8N2)969XTHJAYC)'5+:E
MV(Z'U4>X.OMV7:^4Y)062R&E0KK`\48"N6O<F.P@M?3M#AK>.@6H:E8U;-]I
MZE[U85('[61@I)48POQ$7QVZT!'L$"-5;&D^/XJ^Y<53*&%50AB&'FOGAP/S
M$:X!0@8L0:U9%H:&U6$C,URQV+]`%"@JK!@-YXC#L8M?(VP<.))V=#6IM8"Z
MOK2LEY'N:H(:M2>EAU1)6=_L3S.MQ5Q<5"7=\.-B9MYN"=5]Q88)\]T[-W;1
MZC#V!G*QJRIF<8X%$'#1P0Y05-X=DQ,&KT2)B_U+E[/(@^1CKY!C!HG5Q'*H
M@EX+QE9%%:J2KH`2`"6:@R&V!R?[8Q<2&;LSC13$.A6]*SK6BNK*:^T@,&]"
MUOM!Z4G/=!TNALI7*Z'>T8@J7]DL!DERW>$BH*6E]X1TJ`<62ZS4\,^TGH1'
M08$R3.->KQP)-$CH))IH(E1%N.UV.MT^TG;=;/%:9E\1;*BPY#*J8;0R"-(4
M$9C?X]':6+N%B%`#.Q)HFQ\S-2,Z?`S3"!Y&L#9$"B_([L;2R&2\.#+>MKLG
MLM`JMG`:W1[3N=8UN^8E3M\3:R"/#%E8:'9=+C*2DBPUY_J1J1$VNP2#*N1S
M)V_GA7;-"IG;G9(KG(8K4PG,53":W%\;SM'C;[*UOO?>NDL<!E(.,N/W2L:E
MF:V,DLRAKF50"P]1I=M/O<399&HP]@([=.KQ23]L@3'($=7H(Z%P`@8F@9RP
M%005ON-XL&E(8U6+M9MEI&DYUSIP>H7VA65SGEB<T&<FZI/2<3,5J[Q%65B[
MC6I]HT"1C7BI"K-DWZQ5T0\4DT];#K<35ML,K`373Z;)\<RY8,A%FA7*2.:,
M$-"6NCD5C8Z#V,T0%PI)7-YF9+GMCX,^1EP;''W>'%-'*RN(V>*H;'EH"X-"
MT;E:%S)W$<4H1)?<-B_^8=VY3FV63@;WEFBZ)"P&3GC*>:C1;//[]^(0.<7*
M(<U_\DF;!H42R2=*O4I!!Y[9A$[`$DRII&21:70CRK"\.;`B.JR,>*23)_=,
M[$PM+)+%)=8BJU4M"-&+*-<06Z;-MMKE:+8>3Q94T>UPYYXTQR5$-89"J1-&
M59F>4>VZMS,RF.@M'12PVWST3NO.BPP^>V.Y3SO2>/97]-@I6J,IN+^SP2GK
MO!<K6N;K441"$67,18!<>\XE-X)#V$.@/*,*#*\:\9QILF''PTP,T+*ZRD.5
MS)33V*YJP*E5"VK6I<WBC_7YN;%M]M+#CO/DA\0=L,@H3`+Z.2%M7_(#<>G(
MZX>^YI)\C]680'P93+]49\9W^B9DYDY&`=SV:ZM2=IJ,[1Y9=>OOYN-.F:7C
MD4WOQG:B3B-<+MS>7F8"#Z#8#QK239,<L>3JFVL<$U%?MS0RXLZR55@K$`&Y
M0RBKJK?I'2C98C^3;>.'(ADP]H=/)(E70RX\PGC[3`H2+@14D/0J;>:D@)W*
MMZ$CR$_KST':6,?6-SV?8-.>7**@WZ#]#/HN)X[VJ/JU#@7ZI7;5^TJZ2B[X
MYCD40/-2#I7]X"0!T$<^I'CWD6O\>E:;Q[7XN,D99"!D,^4&DF?@%2S!46E&
M[2J!:+J5)@[Q\W29F^55W4V8\LW;(I%;BO&D:$M]GN9V`5@9&-:"G1%A=NWJ
M(2O&,3=WN%GW'CC<-4T_0Y-.!HC(VFX)"5:9MF.-T6C"FEA8]GIKF5B84XL2
M(2:;R+E1(J`I?M"R]!XWF/%OL#%B@\?V<6/C8J7RD19CR(F3>\DU]8`)9+R#
M$0\0MH2>BL/<[C$$^FV62^1NM>TT\K*D:&7%"EX/99;^Z6$=(ZD&-ZL"*=;,
MTT3DW:,TK&QH:X<:O/<=;=;[=-V=AFPP]ITZ8S=M?*H/'2K0T8I(MH;-'J3Q
MI('GG"I'R")RG;KJHG<E^9FJ\2Q-P-)EX8,R[2%%CB,PDBQN_P!N1<V5B%+R
MJ5,?:!*$CW@-;T-ILWR#:1+NAESP84V%<Q?L&-Y6B[BC$B9+T$/(D:4T=E86
M,`9.N;%VSENXX\<=]BB=5L^P3-ZIM9U'6LLJZ..TC2']1-G35:6+AY'%.=Q\
MJYA;/)MY!ZR>**J2)_6U2<MR+>LU[ZWPV/RK9:23$BQ,/'RVQ\;)G3*:&\RF
MT9:]T&,R1JP4BVPW.:V5Z\SGRLZ7`VNMS,C-EG2*:;'4X\4KQE+C\=V2@",Z
M%E:_NJH0,+R2ZU'TG+;UQ/@]'N][)=,DM65@YMU[O4*VJ8SM7E8U2+GWESA&
M"#-A`N%45E49))%-%N@H"G@!$P#M@,S3;K`\T?5:W&./NHLJZ*%'$A1E_=C"
M.U+P%HREN2*7"ZHZVV-GZR;QD9V;*TNJ;'/<>9:,R4*OW%50`?4/1:#GZ=).
MV>WW@'?\BS*DW1QM/&#9@NT)E]`L3PLSH6-RE3SV=O\`%M*E8V_D[M^2BPK@
MM2I.3'7CA<HD2.)?'V;A<?7_`-A:G-VV?C_"\FUYB,\J>V/)$LMC=Q2*)D$L
M6!X!"FM111AV;,_KS,Q,/7S-F>,Y1F"8S>Z:$JDD]T$G-\7`1E>BQK1@P]U=
MM%T[=)FN?UWZ9(;W,S2O*RXF/I%:805';4=@UL6#Z;I\-`51-K6T;!&I4>:K
MC5BHDX?.E'XH*"Z.)^J,_6Z/"S/)-5+K(HGU40$),DG<JF7!$SO<Y#M+&Q)*
M*H2ZJ*H]"(,S:YJZ3:P[#(>+8SGN+&J=D*89I445C#H(W54))_=H0]:BF[,^
M26T6'-?Z]+#*:2@\G]IWG0,]U-O]%26YKI!0+/772?@FWCT@@U80]&:$,6.(
MW5/[1*J(G[`8K8^(:''V7DN,F.?BX&KAF@:LPLD98#_\F!O+M4.S*`"$-.0-
M@>1[N;7:"=\M6R,S8213+;%=)&#+Z`#CMA%N*A30DGW4!&CG2K[IT'Q]_D6^
M*RLY"_VI7G-(:P-XJM0+Q&O4I/4:[7VJ#".CB11WK5(A2E4406.94X`J)S#^
MK-]%KM8VV740*L(\4QLAD<RL&9Y,=Y06+!A5:TM:T@4X#,`3L,O+G&!'F2O*
M6\ADB1P(U,:IWD0>T%25MJ+A6O#@T/4?9[_?K%;YK'[/;W]Y@,:_L4X<P=(O
MSUI6&D^9K<X6/MT[4Y56%BXNMR<YG\JZ!0BYF95@0=H$7(8Y/(U_B6%JL#';
M;P1C'R<_Q39&6(WF,-&ZK&Z7$N!.%I2I4<E&Y-HF;G[&7-ETDLYG7$WF`$<@
M(X26CE2P`#-$?<"$-U+&%"UK[X#?;RYWSE%C%BN,CHM7RA?)).I6F7CJ\UFX
MA;0*G(2E@HDZ_K,7!1DJZAW,8B^;J"T(Y3;214UC&\4S&YAY#KL(>-ZK>X^/
M'BY.6<A'1&<B01.H655=G*"C%"+@"5#!>:G5Z'/S_P#L6RT>3)+D8N*('CE9
M4%O=5BT)9`+F6@;E00K"M:CH4\#SH5^_\WJ):%@1U8O+/0+[,MI(J:,Y+YY<
M6,$KF%B0$2)G?UT:ZT!J@HEY(-U4%$OVF[@+K^Q"V;@Z+:8@8ZC\+C8X(KVU
MGA4K.@XX8MRU>6:[Z`47^%Y&+C;7=:60"/;1[*29@009(IZ212"[EP`;2P]H
M(`X)IU<IO6;'J7+,N!4;424FB5S$9/2):PT5.HS%EN5W&]KT5W66<K98>T0S
M*.SHK,JTHBW:F=_,?-TEE$R%,F<&+18^I\-_['LL4S;&7.2)(I>ZBI`8NZ):
M(R,1-]L;$VE0S+S0],IMG-G>3IIL2=H<%,5Y6=`A[L@D[9C5V#`&&ESJH+>X
M74%*JE1^1')+3M`P+-"ZZ%>CYC=^7>&72\UNCT-=SI<%@T&M)5K0(0)=A,15
M>L+I0X,W9&22T>5\T<*%0]8%1)M]EXGXMI=7L]E+AB2>/"UN7#%)+,.U\MBL
MN.P5E9K2+@S&^SBM3=TGP]MN]CEX>-%DD0G,RL>21(XV69,<,PE!H;&:VRJ@
MI=<;>5`]I.X<D&U3S70+!N,K8_#GXXXKR-<<T?/&<9<,W0TZQ9\,A83PU70E
M6]Z,BS(X^7&K,&I3(%*+7L*AC5;3QKQ:/83:F+"6&0^.#/#]V:Y)SC"8*M\A
M0Q'AZ&XVM;?44"T[[?KK<7;0Y,C@;P8LB&*,J\)R6@-2$#5'M`="*,+2K&M=
M*F]\EJIAM[Y`R6QN+79\_P"9LAC!,P4IE"84BZT1';8G(&=1CRQ,#^5L;8^9
M2H/T)%&36/\`-("9D3H>1>JI/'O$F\F3QYL3M:O*U$>0,@/+W<9SCF9I*.]C
MH&!4QNH)7[71B#T8V[V,&JR-W\QYI8-HT"QA81%*O?$*QBB7`D,*,)*WBI-M
M1T1S<D+Y(ZYC]EH6BW*7R>^\N;9Q\DH^Z0N8LZS:V,=7-05G$:##P\"ST:';
M9M:<_09(RTB^$TJ=58RB!TCH*=`CQ;6PZ3.@V.)'^8ATT>6IA.07@)>$*9F9
MS"YG25FD15I$J44W!J2/R/-;9XTV+/-+K9]J^*`_QPK@)*7,:HG<"PM$`K,X
M=PS7KZ'JH1FT\CVU/;Z3(;>\G%&7]B9N,A:H6CYY!UZ3S!?D.IC3IK(.$8%W
M,'LWUJH.F3U!XW!!<B::B:P>PQ_63I_%US3K8L"Q6\>7-O,LK2)/\5<GVBX(
MT986,I4DHQ(9&`*U1[+R4X/Y%LU7=-U\8($B"2PF<0<FQF5S4O56-MH4@D&I
M:H^I;8[T*S\7;+H<TML]5W@MF3N"=?IK4)KB7(,ORF$L@1J58&&+XH`6H/%2
M(E7"P#\@JH%,")`=CK?'8<.'RG&Q(SHY]8!VR\HMV`;MR(&,EY"M^Z.2.Q[>
M6]Q+Q]CMI,^;Q>;->/<C/+*](2QPBA=2B]NT\`([%24E:I:A5.G;U.(),0!D
MX^1BHVX,VTP^J!Y1^E'HNWB4.\2DXURH8#K&B)"*742>&(13XZ9@7\?)(@AC
MO&,M\38*TL<DFL=XUFM1GM!D4HX`(K(C@-&"1>PL/#$=;7:P)D06APF6`QC-
MP4DVFJ\_I9:AO]`;A0@$)W$/;I]O:6=J@)&*M*K6&8OIN/5JEJ(M'18PCELZ
MJ\:E<H%1E7I)V"#<KAX5!PLR10$J":RRBINE946I;&@;431M""[6.)HV#M>K
M+.Y@</(JW,`@L$C2EB0@3K!0S3C*=9H>UF@*H8&.;]E#$!VPTH)20JM)'`85
M2B7-<9U/;7JS7-=I7HYO3J9(W)9W,RSJP0@-V;QY2;<TEQSYG%3$E((6(K%9
M0#LG14@:-723E)50K`2&IV$^JUV`KY1DR\Z/"`55C:C(N1`8AE%T4&$R!:.A
M(D92A5&F!!VM&ZFRB8UCCUC2_N%F%+2LID[:W-0AC;::`(0;CVZ%[X-.'1AH
MI&O"R&"2CV:<.,:JFO'C&D0(5D+-=$ZB2S86X%\#E,8#%_7N/^>N09ARSER'
M/[GS2Y[E];[Z^ZZ[FZOK7FO6_A$0A08]OQ[%MM^VV@MMIQ2E*4XI2G0.UMCQ
M:D)^+0VP^))VT&S=2&-?Y&FQEK^`11\+<(UQ,.FDV,>*GR>Q4S>DP^W]!_=U
MI?')?.(8Y&\6&R,!!#_'65DI<GW!`5!NLY(J#;S6G23:)XP^5&-Q\+YO-G=,
M8D^UJVW$-2VZM.*5KQ7K[*EQ7&IT(B8X+^$%L1"YB*:U`"LC;@=`"8T90I_K
M3V;YP!V%@(N_=_SY=>8G\X_(9;0_E/RA7_DT$W<MH?YP!<%I7A^*?XZ@7Q?L
MXE/@_'#?\;F*V[C^#Z%N!0IS_P"3U,OB'&A6=L/\EFQ,+,-7+^5_FCBDI3OX
M5\AH!/R#[E0D@%6^6"';Y/\`ZGM\.W[O'KSJW\U7%A_#?DOA=[]KLB8IWO=_
M'8+>Y]WV^[[AZ5ZJV<?B;Y$AVWP?E]E@_=:,-VC9=?<0;/LY/`]OI4=5/ZSA
MNGG$C'&5X^CEH6^*&747EZ*K5/ST#M5X3[.36>G9#;>P(`U!9;YGJ\"$_9V+
MT1D3^>G<B;)&T_.=IJ7),)>U4A_:16RZMW%I>I;W5/7P)XBNK$?_`.?^'NH.
M8C'=:?U$VW65YK=;7Z=3G['B,>^LY"2/@0:*@^@$&:;J0HB=B-+J,HT:H8(T
M[DKAQ-!'?#^L4,D9R5OZ0;F`GAUY27SL:DQ(-I^%_=/"S=OU_?\`=2E+A^Z*
MTNK>*DUDL?B)V*23?C_R@=+:F+N7V_MT%:EK?X^+K?MXZ(M,0QM.VWH^?FSL
M;R:1`=+"IN*\K:?M5'#E0GYN2*5/*%?@N*OK^<`*%_<4O8.X=+MI)Y,VOQAN
M?F?C`B_'[HD$=@0!>R6`6VRVEG!%#_GHS!30C/G?6_%_)$GO=LIW*W&O<"FH
M-U:W"M>M0M\4'6RN!-F_\Y%@``"_)KH:=^+BFH4.[8%0LIH+UB;L(D%#_(]?
M$D\E_`M&GS/^M7^ZBO\`'ON'J:=NZZGUK6@ZLE72';1-+\;\X$:RI0364-UH
M^\K3UX(I_MU7].9\;G%QI!M@/CQ;^"I`SD+^^J36V^]-^DJ7\+).N$9<RPR`
M$`WP0\C'[%'O_CHS1S>9QX$P\=&P_&7'N]A96BN*4_<L!6MGI=Z#D4]>J]@F
MA;,B.S^+\ZTB+N%`]"5K9<0WW!>5]#Q]>8^9U)"#U+:+'9[E5K+IMQ>5MV:$
MAC-VS^D8]$DF(S,(%Y&+.W,P#=W(ISCY5\L";=[)N7@(%*1'Q+1M<PY&HP<?
M"@FBU4`<%FJ5ERFHTSA@`MUAA2T$LL:I7UJ?.NQ7AV.7/ERQ2;"5E*JO!CQU
MJ(E(+$_?W6+@*K,2`/;7J@P<-P<*I:W%<6XW_P#9L;26UEAIZA&:I1R;9T%X
M^4U9R(M(AJ+05ON!3(B4Z?G\KN'?IGDY']@]R$98VG>1HNW>DUUP)[%*K5C=
M=V_4DUMYZ"2/PY<MY5_'_+*M=[HB:<=RJDT`]+^.?U=39R"X7OZ?EK*;7P).
MDI,K(KBYSV*G1L*,69I[+:&:R#:3:I*Q01XA]@2-4,@#?L"H`F`!U3'/YTN;
MFN@V7SB4&7[)2UU1V^^"I(>H]A<!JUM-2>K,F'Q1L+'3*.%\`?PW,@3U_P#6
M:T/-/M/1A.CCRF0.&YASP,(/072+@Q%Z^GEP9D:#5(\$[E-0M83I?XZ)_,_F
M#,&G<1'P_7I%7<#;AO\`D?G>^/H_?[UW''W]R_T_5=_GIL1K3KR#V?Q7:-?M
M[7;H:_\`ULI6OTIT&,?A>$L9<DG6'+<>%+X_@C#'%S^?H\O8B5A),X+_`$+2
M)D7KR.@!3,/N!D1)L<.WGW[!VT6_R/[`FQ+?)1M!A*X_G255N^EQ90"U?2ZI
MK_GI'J(?#(LN[1G7G-8-3M-&STXNM"DD#TN"T'^O05LF8X)/ZOQSL^#7[C?5
MDZ;OE@N<U`0UDB%I'0+>XS'1ZF[J53CJY-`Q;S[6,L,I*N6R2)SB:..<Z/B"
MRA'D6V\FQM1LL7R?'VDOR,".)7DB:V&,3PNLC-(M:$H(U:O-_J2>DF5K='/O
M\/+T4VMBS8LIGD42#N2'MRJ4"(?7WESQ=5/]*]%-I!\"1N9%F"_&7\_>Z0L\
M9`RL6?%M)-7:NE@?$AF[>3"2870SX%/EH-"INEEO(5B&/WZ3//\`V(,5Q*-M
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MXNOR##%%**K7VTV\)-J462B9=$UE$B!I`9^2C'3U9W8?29+W&=JG=>OP`P^(
M%#K/[>3=2SJ^\^0)S&+>ZK+[*>VP,``M/2T4Z:ZI-3'B!--V/AAC_$59:UYJ
M5)J?]:FO0SW."X@3MBKZ7(1?$$+@VCG2U;'0K%5:[:S0ODJ5X6.6D9.,FW4'
MY^?M3*8[7S[B8._?IUX_D>=8^'(?&AL3KR2'["2O%=05K:K(&I3GAJ4YITOV
MD?BTF?%^7^%^4"UC[C1B6WG[;B'*UKQROKQZ]>VB$X@356SZ/LBV'(U1-C,*
M9:H2P52!9#%)(&)8PHLG&R4<HI%"W/\`]B1@J*!P["N`]@$*\2?S:#-FDQ1L
M3G402^R5VH0.WW`P;]-O;+"H%+.*=>&A\3?"Q(B<+X(K\:C(%X7W=E@17VUN
ML/(K=4=?<9#\0U'V&KP:V&`^8-Y!/CH6%G:BD91N@F[&9')V\=($))`9#W_.
M-&%5%0GG[A,'EU7/-YB%SURAGVL5^;>LE:U6SY!857FRT.1S;3Z=$)'XXTV*
MT1Q.^`?CVL@-.:]H*>16MUM0>:]50E6X+C3X9LBZX_?@Y->%Q7S)7&J!7AW8
M':B1BQ;I.;^&IJ'V13B*29QD_E>9A+[1,(LY,S^Q3G2-,-G^0.!1ZQ2=SX=`
M>04J,>E.>$MH*V\=!C'\0[`L.%V#D&WWI;WZFMONH):U^WW`U^O0IP++L+I,
MG(N-5O?'J\Z+(<EM4M6:NHRWQ[IS#6ZW6^:E0I["'FI42N=&J<LX?-/]"!GR
M*A#@4J1P.4&GDNV\BV"H=;C;/&UXU\:2JT;`&-(U4R7!>(I(PC,.$Y^H-2GT
M6NT&$7^?/KY\QL]VC(=21(S*0E"?YEDJ!07>E`";02DZSP$-<G3M%SQM"]/]
M1>.3D0MM))/I[(V>#]J6/8I317,;H1I`X?.2;)I/U5NWO*8P!V"^;_9PPE6F
MV^`N*!_%+9\<J:7&RC1676EB5"W4-">B\C$\`DF+9!UO?;)7_P!D:GY`]*`,
M*3?[4<_6O4E*J<$@I:J"+KC[^`&U$RRID[E5!K'\S&=((&`SDLZ,>71_LBIB
M"?D$B#OL<`]H^7529O\`8XG%@VGR?C"G[4E_QZDBGLN[-:^G[?T]..K9\7P9
ML5AD'7_".6;JR($^35@:^Z@FNNJ/ONJ?NZ(])J:4?NVG6^U6^H2MTGZQ5H:@
M4^'6;)S51Q&OKO5&SR1:N%/NGKJS7^6DE';P"BP$&[1!(?8BH)TVPS'DT&-A
M8T,RX,<\CRR,/;)E.J!E!`M`CC5;5^_W.QX(`8XF+"GD&3EY4L#;-X46-%([
3B8RL34@FXWRLQ9@`M0J@DCK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
